Castle Biosciences Inc (CSTL)

$24.51 +0.33 (1.36%)
Market Cap 710.99M
Revenue (ttm) 332.07M
Net Income (ttm) 18.25M
EPS (ttm) N/A
PE Ratio 69.09
Forward PE N/A
Profit Margin 5.50%
Debt to Equity Ratio 0.02
Volume 198,900
Avg Vol 365,174
Day's Range N/A - N/A
Shares Out 29.01M
Stochastic %K 87%
Beta 1.13
Analysts Strong Sell
Price Target $35.62

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 788 9007
Address:
505 S. Friendswood Drive, Suite 401, Friendswood, United States
RocketThief
RocketThief Oct. 22 at 2:52 PM
$CSTL strong heading into earnings, and they never miss
1 · Reply
Dream2121
Dream2121 Oct. 22 at 1:14 PM
$CSTL Zacks just upgraded rating to STRONG BUY! https://www.zacks.com/stock/research/CSTL/stock-style-scores
0 · Reply
BioTechNoir
BioTechNoir Sep. 26 at 4:50 PM
$CSTL https://www.prnewswire.com/news-releases/scibase-receives-initial-order-for-clinical-study-from-castle-biosciences-302564012.html
0 · Reply
RocketThief
RocketThief Sep. 12 at 7:08 PM
$CSTL low volume dip, adding as it falls
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 4:24 PM
$CSTL Outstanding article that hits the mark on CSTL's current state. So if you want to refresh your CSTL insights or learn about CSTL from scratch, this is a must read. https://beyondspx.com/quote/CSTL/analysis/castle-biosciences-unlocking-value-through-precision-diagnostics-and-strategic-expansion-nasdaq-cstl
1 · Reply
TheBearVsTheBull
TheBearVsTheBull Sep. 4 at 3:32 PM
$LUCD $EXAS $ABBV $CSTL $MRK Anyone else who registered to the MolDX CAC meeting today should have received an email from MolDX and it looks like they CC’d everyone on the email. I see a lot of interesting names on there such as people from Exact, Abbivie, Merck, and CastleBiosciences 👀.
2 · Reply
BioTechNoir
BioTechNoir Sep. 2 at 6:42 PM
$CSTL GREEN
0 · Reply
BioTechNoir
BioTechNoir Aug. 29 at 1:28 AM
$CSTL when $30
0 · Reply
DarthGoat
DarthGoat Aug. 28 at 4:32 PM
$CSTL OOOOUUTTT +18%
0 · Reply
MetaverseEdge
MetaverseEdge Aug. 23 at 10:23 AM
$CSTL Castle Biosciences Inc is facing diagnostic adoption challenges and reimbursement pressure
0 · Reply
Latest News on CSTL
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Oct 24, 2025, 4:05 AM EDT - 1 day ago

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Oct 13, 2025, 7:00 AM EDT - 12 days ago

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Oct 1, 2025, 4:30 PM EDT - 24 days ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Sep 23, 2025, 7:00 AM EDT - 4 weeks ago

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

Sep 2, 2025, 9:14 AM EDT - 7 weeks ago

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Aug 25, 2025, 7:00 AM EDT - 2 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences to Participate in Upcoming Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:21 PM EDT - 2 months ago

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Castle Biosciences Reports Second Quarter 2025 Results

Aug 4, 2025, 4:05 PM EDT - 2 months ago

Castle Biosciences Reports Second Quarter 2025 Results

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Jul 25, 2025, 7:00 AM EDT - 3 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Jul 23, 2025, 7:00 AM EDT - 3 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Jul 17, 2025, 7:00 AM EDT - 3 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Jul 14, 2025, 7:00 AM EDT - 3 months ago

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 19, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Jun 16, 2025, 4:30 PM EDT - 4 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 29, 2025, 4:30 PM EDT - 5 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 5 months ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 9, 2025, 7:00 AM EDT - 6 months ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 7, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:58 PM EDT - 6 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:06 PM EDT - 6 months ago

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences to Acquire Previse

May 5, 2025, 4:05 PM EDT - 6 months ago

Castle Biosciences to Acquire Previse

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

May 2, 2025, 4:30 PM EDT - 6 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Apr 30, 2025, 5:00 PM EDT - 6 months ago

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Apr 28, 2025, 7:00 AM EDT - 6 months ago

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Apr 25, 2025, 4:15 PM EDT - 6 months ago

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Apr 8, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Apr 7, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

Apr 3, 2025, 7:00 AM EDT - 7 months ago

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Apr 1, 2025, 4:30 PM EDT - 7 months ago

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Mar 28, 2025, 4:15 PM EDT - 7 months ago

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Mar 7, 2025, 7:00 AM EST - 8 months ago

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:09 PM EST - 8 months ago

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

Feb 27, 2025, 4:05 PM EST - 8 months ago

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Feb 12, 2025, 4:30 PM EST - 9 months ago

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Feb 6, 2025, 7:00 AM EST - 9 months ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Jan 17, 2025, 7:00 AM EST - 10 months ago

Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Jan 12, 2025, 6:00 PM EST - 10 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test

Jan 6, 2025, 7:00 AM EST - 10 months ago

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Dec 23, 2024, 7:00 AM EST - 10 months ago

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Dec 12, 2024, 7:00 AM EST - 11 months ago

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 1 year ago

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Nov 19, 2024, 7:00 AM EST - 1 year ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Nov 8, 2024, 7:00 AM EST - 1 year ago

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test

Nov 7, 2024, 7:00 AM EST - 1 year ago

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test

RocketThief
RocketThief Oct. 22 at 2:52 PM
$CSTL strong heading into earnings, and they never miss
1 · Reply
Dream2121
Dream2121 Oct. 22 at 1:14 PM
$CSTL Zacks just upgraded rating to STRONG BUY! https://www.zacks.com/stock/research/CSTL/stock-style-scores
0 · Reply
BioTechNoir
BioTechNoir Sep. 26 at 4:50 PM
$CSTL https://www.prnewswire.com/news-releases/scibase-receives-initial-order-for-clinical-study-from-castle-biosciences-302564012.html
0 · Reply
RocketThief
RocketThief Sep. 12 at 7:08 PM
$CSTL low volume dip, adding as it falls
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 4:24 PM
$CSTL Outstanding article that hits the mark on CSTL's current state. So if you want to refresh your CSTL insights or learn about CSTL from scratch, this is a must read. https://beyondspx.com/quote/CSTL/analysis/castle-biosciences-unlocking-value-through-precision-diagnostics-and-strategic-expansion-nasdaq-cstl
1 · Reply
TheBearVsTheBull
TheBearVsTheBull Sep. 4 at 3:32 PM
$LUCD $EXAS $ABBV $CSTL $MRK Anyone else who registered to the MolDX CAC meeting today should have received an email from MolDX and it looks like they CC’d everyone on the email. I see a lot of interesting names on there such as people from Exact, Abbivie, Merck, and CastleBiosciences 👀.
2 · Reply
BioTechNoir
BioTechNoir Sep. 2 at 6:42 PM
$CSTL GREEN
0 · Reply
BioTechNoir
BioTechNoir Aug. 29 at 1:28 AM
$CSTL when $30
0 · Reply
DarthGoat
DarthGoat Aug. 28 at 4:32 PM
$CSTL OOOOUUTTT +18%
0 · Reply
MetaverseEdge
MetaverseEdge Aug. 23 at 10:23 AM
$CSTL Castle Biosciences Inc is facing diagnostic adoption challenges and reimbursement pressure
0 · Reply
Dream2121
Dream2121 Aug. 16 at 7:36 PM
$CSTL Their Attopic Dermatitis test will come out before the end of the year. It will eliminate the Trial and Error in picking the right systemic medication in treating eczema. I think this will be huge because eczema is such a common condition among almost all ages.
0 · Reply
TommyRubin
TommyRubin Aug. 12 at 3:33 PM
$CSTL
0 · Reply
DarthGoat
DarthGoat Aug. 6 at 1:58 PM
$CSTL IIIIIINNNNNNN
0 · Reply
topstockalerts
topstockalerts Aug. 6 at 1:16 PM
Top Gainers PT2 $XMTR $OTRK $ZEPP $AIP $CSTL
0 · Reply
P3anutButt3r
P3anutButt3r Aug. 6 at 11:41 AM
$IXHL I know, I know... Serious question though, why is $CSTL experiencing volatility with no volume? 🤔 How is that possible?
0 · Reply
StockScanners
StockScanners Aug. 5 at 10:31 PM
$CSTL Reached 21.33
0 · Reply
topstockalerts
topstockalerts Aug. 5 at 8:49 PM
Top Gainers PT2 $XMTR $OTRK $ZEPP $AIP $CSTL
0 · Reply
topstockalerts
topstockalerts Aug. 5 at 7:55 PM
Top Gainers PT2 $XMTR $ZEPP $AIP $CWD $CSTL
0 · Reply
lecorb
lecorb Aug. 5 at 6:51 PM
$CSTL $XMTR $AMRC $LMND Etc.. Big Day!
0 · Reply
Leadballoon
Leadballoon Aug. 5 at 6:12 PM
$CSTL Flailing begins shortly.
0 · Reply
airbell
airbell Aug. 5 at 3:59 PM
$CSTL sold! hope to see you 😊
0 · Reply
topstockalerts
topstockalerts Aug. 5 at 2:16 PM
Top Gainers PT2 $CSTL $AMRC $ADAP $LMND $CWD
0 · Reply